Innoviva (INVA) Intangibles (2013 - 2026)
Innoviva's (INVA) quarterly Intangibles came in at $175.6 million in Q1 2026, down 32.9% YoY from $261.7 million in Q1 2025, and down 3.6% on a QoQ basis from $182.2 million in Q4 2025.
Innoviva (INVA) Intangibles (2013 - 2026) Analysis & Trends
Innoviva (INVA) has 7 years of Intangibles data on file, last reported at $175.6 million in Q1 2026.
- Quarterly Intangibles fell 32.9% year-over-year to $175.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.6 million (down 32.9% YoY) and the FY2025 annual result came in at $182.2 million, down 30.4% from the prior year.
- Intangibles retreated to $175.6 million in Q1 2026, from $182.2 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $261.7 million in Q4 2024 to a low of $105.0 million in Q1 2022.
- A 5-year average of $219.1 million and a median of $243.4 million in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles soared 136.49% — and 2026, when it slumped 32.9%.
- Tracing INVA's Intangibles over 5 years: stood at $258.5 million in 2022, then declined by 10.9% to $230.3 million in 2023, then advanced by 13.62% to $261.7 million in 2024, then plunged by 30.4% to $182.2 million in 2025, then slipped by 3.6% to $175.6 million in 2026.
- The last three Intangibles figures came in at $175.6 million (Q1 2026), $182.2 million (Q4 2025), and $188.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 261.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 261.70 Mn |
| Mar 31, 2026 | 175.60 Mn |
| Dec 31, 2025 | 182.16 Mn |
| Sep 30, 2025 | 188.79 Mn |
| Jun 30, 2025 | 195.41 Mn |
| Mar 31, 2025 | 261.70 Mn |
| Dec 31, 2024 | 261.70 Mn |
| Sep 30, 2024 | 257.70 Mn |
| Jun 30, 2024 | 257.70 Mn |
| Mar 31, 2024 | 257.70 Mn |
| Dec 31, 2023 | 230.34 Mn |
| Sep 30, 2023 | 236.85 Mn |
| Jun 30, 2023 | 243.36 Mn |
| Mar 31, 2023 | 248.31 Mn |
| Dec 31, 2022 | 258.50 Mn |
| Sep 30, 2022 | 258.49 Mn |
| Jun 30, 2022 | 105.00 Mn |
| Mar 31, 2022 | 105.00 Mn |
| Sep 30, 2014 | 211.65 Mn |
| Jun 30, 2014 | 194.88 Mn |